| Abstract: |
This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital. |
| Inventor: |
Whalley, Ben (Reading, GB); Williams, Claire (Reading, GB); Stephens, Gary (Reading, GB); Futamura, Takashi (Osaka, JP) |
| Applicant: |
GW Pharma Limited (Salisbury, GB); Otsuka Pharmaceutical Co., Limited (Tokyo, JP) |
| Face Assignee: |
GW Pharma Limited (Wiltshire, GB); Otsuka Pharmaceutical Co. Limited (Tokyo, JP) |
| Filed: |
2015-04-14 |
| Issued: |
2020-10-13 |
| Claims: |
6 |
|
US10799467
|
1. A method for the treatment of partial seizures, which comprises administering to a subject in need thereof a therapeutically effective amount of the phytocannabinoid CBDV, wherein the CBDV is present as the only active cannabinoid.
(2)
(0)
|
|
